证券研究报告 从保值到颜值，再到情绪价值 零售行业2026年度投资策略 姓名 黄泽鹏（分析师） 证书编号：S0790519110001 邮箱：huangzepeng@kysec.cn 姓名 姚慕宇（联系人） 证书编号：S0790125040021 邮箱：yaomuyu@kysec.cn 姓名 李昕恬（联系人） 证书编号：S0790125100021 邮箱：lixintian@kysec.cn 2025年11月2日 核心观点 1.行业回顾 2025年社会消费和零售企业经营缓慢复苏，具体分板块看：黄金珠宝受金价高涨影响，高端中式黄金和时尚黄金赛道呈现更高景气， 化妆品医美竞争激烈、国货品牌崛起，线下零售企业则持续推进模式变革探索。值得注意的是，"情绪消费"仍是景气度重要密码。 2. 细分板块梳理分析 黄金珠宝：行业核心逻辑已发生深刻变化：金价高涨、婚庆下滑，传统渠道品牌竞争力削弱，同时情绪消费兴起叠加社媒传播助力， 部分具备差异化产品力和消费者洞察力的新兴产品型品牌崛起，在爆款打造、终端销售和加盟商开店等多维度验证竞争优势，品牌 势能亦持续提升，建议关注高端中式黄金和年轻时尚黄金等细分赛道机会。 零售电商：线下零 ...

证券代码：603193 证券简称：润本股份 公告编号：2025-046 润本生物技术股份有限公司 关于使用部分暂时闲置募集资金进行现金管理 到期赎回的公告 截至本公告披露日，公司本次使用募集资金进行现金管理的情况如下： 1 | | 中国银行股 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2 | 份有限公司 | 结构 | 结构 | 13,200,000.00 | 3.09% | 202,263.78 | 2024/11/ | 2025/5/ | | | 广州珠江支 | 存款 | 存款 | | | | 12 | 12 | | | 行 | | | | | | | | | | 中国银行股 | | | | | | | | | 3 | 份有限公司 | 结构 | 结构 | 163,200,000.00 | 1.05% | 859,147.40 | 2024/11/ | 2025/5/ | | | 广州珠江支 | 存款 | 存款 | | | | 12 | 14 | | | 行 | | | | | | | | | | 中国银 ...

证券之星消息，10月31日个护用品板块较上一交易日上涨1.02%，稳健医疗领涨。当日上证指数报收于 3954.79，下跌0.81%。深证成指报收于13378.21，下跌1.14%。个护用品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300888 | 稳健医疗 | 41.30 | 2.00% | 10.02万 | | 4.13亿 | | 301108 | 洁雅股份 | 32.20 | 1.61% | 2.87万 | | 9267.85万 | | 6005009 | 豪悦护理 | 32.60 | 1.46% | 1.69万 | | 5508.33万 | | 301009 | 可靠股份 | 13.57 | 1.42% | - 3.36万 | | 4555.22万 | | 600249 | 两面针 | 6.20 | 1.31% | 11.28万 | | 6997.05万 | | 603193 | 润本股份 | 26.55 | 1.10% | 2.51万 | | ...

10月30日，润本股份跌0.83%，成交额4992.79万元。两融数据显示，当日润本股份获融资买入额478.49 万元，融资偿还1072.10万元，融资净买入-593.60万元。截至10月30日，润本股份融资融券余额合计 3.15亿元。 融资方面，润本股份当日融资买入478.49万元。当前融资余额3.14亿元，占流通市值的11.58%，融资余 额超过近一年80%分位水平，处于高位。 融券方面，润本股份10月30日融券偿还300.00股，融券卖出1600.00股，按当日收盘价计算，卖出金额 4.20万元；融券余量9100.00股，融券余额23.90万元，超过近一年80%分位水平，处于高位。 资料显示，润本生物技术股份有限公司位于广东省广州市天河区珠江新城华夏路28号40楼，成立日期 2013年12月30日，上市日期2023年10月17日，公司主营业务涉及驱蚊类、个人护理类产品的研发、生产 和销售。主营业务收入构成为：婴童护理系列产品45.26%，驱蚊系列产品41.92%，精油系列产品 10.29%，其他产品2.47%，其他(补充)0.06%。 责任编辑：小浪快报 截至9月30日，润本股份股东户数2.62万，较上 ...

润本生物技术股份有限公司 2025 年第三次临时股东会会议资料 润本生物技术股份有限公司 2025 年第三次临时股东会 会议资料 2025 年 10 月 31 日 1 润本生物技术股份有限公司 2025 年第三次临时股东会会议资料 二、为保证本次会议的严肃性和正常秩序，请出席会议的股东或股东代理人 （以下统称"股东"）及相关人员准时到达会场签到确认参会资格。 1、个人股东亲自出席会议的，应出示本人身份证或其他能够表明其身份 的 有效证件或证明、股票账户卡；委托代理他人出席会议的，代理人应出示本 人有效身份证、股东授权委托书。 2、机构股东应由法定代表人、执行事务合伙人或者委托的代理人出席会议。 法定代表人、执行事务合伙人出席会议的，应出示本人身份证、能证明其具有 资格的有效证明；委托代理人出席会议的，代理人应出示本人身份证、机构股 东加盖公章或法定代表人、执行事务合伙人签字的书面授权委托书。 目 录 | 2025 | 年第三次临时股东会须知…………………………………………………3 | | --- | --- | | 2025 | 年第三次临时股东会议程…………………………………………………5 | | | 议案 ...

Investment Rating - The report adjusts the investment rating to "Accumulate" based on the company's performance and market conditions [4]. Core Views - The company, Runben Co., Ltd. (603193), achieved a revenue of 1.238 billion yuan in the first three quarters of 2025, representing a year-on-year increase of 19.28%, while the net profit attributable to the parent company was 266 million yuan, up 1.98% year-on-year [2][3]. - In Q3 2025, the company experienced a revenue growth of 16.67% year-on-year, but the net profit decreased by 2.89% year-on-year, indicating pressure on profitability [3]. - The gross margin declined slightly to 58.27%, and the net profit margin decreased to 21.50%, primarily due to increased sales and financial expense ratios [3]. - The mosquito repellent product line saw significant revenue growth in Q3 2025, driven by the chikungunya virus outbreak and changes in product structure, with revenues reaching 132 million yuan, a year-on-year increase of 48.54% [4]. Summary by Sections Financial Performance - For the first three quarters of 2025, the company reported a revenue of 1.238 billion yuan and a net profit of 266 million yuan, with a slight decline in the net profit margin [2][3]. - The average selling price of mosquito repellent products increased by 12.04% in Q3 2025, contributing to the revenue growth [4]. Profitability Analysis - The company's gross margin decreased by 0.06 percentage points to 58.27%, and the net profit margin fell by 3.65 percentage points to 21.50% due to rising sales and financial expenses [3]. Future Outlook - The report revises the earnings per share (EPS) forecast for 2025-2027 to 0.80, 0.94, and 1.08 yuan per share, respectively, reflecting adjustments in profit expectations [4]. - The price-to-earnings (PE) ratios for 2025, 2026, and 2027 are projected to be 33, 28, and 24 times, respectively, based on the adjusted EPS [4].

Group 1 - The core viewpoint of the articles highlights the recent trends in stock recommendations and target price adjustments by brokerages from October 20 to October 26, indicating significant movements in the market [1][2]. Group 2 - During the period, brokerages issued a total of 326 target price adjustments, with notable increases for Zhongrun Optical and Guibao Pet, showing target price increases of 74.39% and 66.37% respectively, belonging to the computer equipment and feed industries [1]. - A total of 381 listed companies received brokerage recommendations, with Yanjing Beer receiving the highest number at 21 recommendations, followed by Ningde Times with 20 and Runben Co. with 18 [1]. - Five companies had their ratings upgraded, including Huatai Securities raising Shuangliang Energy's rating from "Hold" to "Buy," and Huayuan Securities upgrading Huayou Cobalt from "Hold" to "Buy" [1]. - Conversely, five companies experienced rating downgrades, such as Zhongyou Securities lowering Shenma Power's rating from "Buy" to "Hold," and Tianfeng Securities downgrading Dirui Medical from "Buy" to "Hold" [1]. Group 3 - In terms of initial coverage, brokerages provided 65 first-time ratings, with Yanjiang Co. receiving a "Buy" rating from Tianfeng Securities, and Qianfang Technology and Zhongyao Holdings both receiving "Buy" ratings from Dongwu Securities [2]. - Other companies like Yingluohua and Yipuli also received ratings, with Yingluohua getting an "Increase" rating from Hualong Securities and Yipuli a "Buy" rating from Global Fortune Management [2].

Core Viewpoint - Runben Co., Ltd. (603193.SH), known as the "first stock in mosquito repellent," reported a year-on-year increase in revenue and net profit for the first three quarters of 2025, but the capital market reacted negatively, with a stock price drop of over 4% the day after the earnings release. The main concerns are insufficient growth momentum and weakening profitability indicators [1][5]. Financial Performance - The company achieved a total revenue of 1.238 billion yuan for the first three quarters, representing a year-on-year growth of 19.28% [5]. - The net profit attributable to shareholders was 266 million yuan, up 1.98% year-on-year, while the net profit excluding non-recurring gains and losses decreased by 1.79% [5][6]. - In Q3 alone, revenue was 342 million yuan, a 16.67% increase year-on-year, but net profit fell by 2.89% to 78.52 million yuan [6][8]. Product Performance - The company's product structure is shifting, with the baby care series becoming the most significant revenue source, contributing 52.4% to total revenue, surpassing the mosquito repellent series at 33.3% [6][7]. - In Q3, the mosquito repellent category saw a revenue increase of 48.54% due to heightened demand from the outbreak of the Chikungunya virus, while the baby care products faced a 9.81% decline in sales volume [7][8]. Marketing and R&D Investment - The company's sales expenses reached 370 million yuan, a 30.92% increase, leading to a sales expense ratio rise from 27.25% to 29.92% [9][10]. - R&D expenses were 25.14 million yuan, a slight increase of 2.12%, but the R&D expense ratio decreased from 2.4% to 2.0%, indicating a growing imbalance between marketing and R&D investments [10].

Core Viewpoint - Runben Co., Ltd. (603193.SH), known as the "first stock in mosquito repellent," reported a year-on-year increase in revenue and net profit for the first three quarters of 2025, but the capital market reacted negatively, with a stock price drop of over 4% the day after the earnings release. The main concerns are insufficient growth momentum and weakening profit indicators [1]. Group 1: Financial Performance - For the first three quarters, Runben achieved a revenue of 1.237 billion yuan, a year-on-year increase of 19.28%, while net profit attributable to shareholders was 266 million yuan, up 1.98%. However, the net profit excluding non-recurring gains and losses decreased by 1.79% to 251 million yuan [5]. - In Q3 alone, the company reported a revenue of 342 million yuan, a 16.67% increase year-on-year, but net profit fell by 2.89% to 78.5 million yuan, with a decline of 7.58% in net profit excluding non-recurring items [6]. Group 2: Product Performance - The company's product structure has shifted, with the baby care series becoming the most significant revenue source, contributing 52.4% to total revenue, surpassing the mosquito repellent series at 33.3% and the essential oil series at 12.0% [7]. - The mosquito repellent category generated 508 million yuan in revenue, a 20.88% increase, while the baby care category saw a revenue of 551 million yuan, up 24.64%. However, the essential oil category experienced a decline of 7.02% [7]. Group 3: Marketing and R&D Investment - The company's sales expenses reached 370 million yuan, a 30.92% increase, with the sales expense ratio rising from 27.25% to 29.92% [10]. - The R&D expenses for the first three quarters were 25.14 million yuan, a slight increase of 2.12%, but the R&D expense ratio decreased from 2.4% to 2.0%. The ratio of sales expenses to R&D expenses has expanded to 14 times, up from 11.5 times the previous year, indicating a "light R&D, heavy marketing" approach [11].

Market Overview - The personal care products sector experienced a decline of 0.34% on October 24, with Baiya Co., Ltd. leading the drop [1] - The Shanghai Composite Index closed at 3950.31, up 0.71%, while the Shenzhen Component Index closed at 13289.18, up 2.02% [1] Stock Performance - Key stocks in the personal care sector showed varied performance, with the following notable changes: - Baiya Co., Ltd. (003006) closed at 22.77, down 1.94% with a trading volume of 63,800 shares and a turnover of 146 million [1] - Yanjing Co., Ltd. (300658) closed at 8.46, down 1.40% with a trading volume of 168,400 shares and a turnover of 145 million [1] - Jeya Co., Ltd. (301108) closed at 35.76, down 0.91% with a trading volume of 49,800 shares and a turnover of 185 million [1] - Other stocks like Beijia Co. (603059) and Zhongshun Jierou (002511) also saw minor declines [1] Capital Flow - The personal care products sector saw a net inflow of 2.96 million from institutional investors and a net inflow of 4.80 million from retail investors, while retail investors experienced a net outflow of 7.76 million [3] - Notable capital flows for specific stocks include: - Wanjian Medical (300888) had a net inflow of over 9.34 million from institutional investors, but a net outflow of 11.91 million from retail investors [3] - Liangmian Needle (600249) saw a net inflow of 7.46 million from institutional investors, while retail investors had a net inflow of 1.39 million [3] - Baiya Co., Ltd. (003006) had a net inflow of 5.32 million from institutional investors but a significant net outflow of 4.30 million from retail investors [3]